Study of two drugs before and after radiotherapy for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a combination of two drugs (Becotatug Vedotin and Putlimab) before surgery and then radiation after surgery can help people with locally advanced head and neck squamous cell carcinoma. It aims to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of head and neck cancer called squamous cell carcinoma that is locally advanced (has spread nearby but not to distant parts of the body).
- You cannot have had any prior treatment for this cancer, such as chemotherapy, radiation, or immunotherapy.
- You must not have active hepatitis B or C, HIV, or an autoimmune disease requiring systemic treatment.
- You must not have had any other cancer in the last 5 years, except for certain skin cancers or fully removed carcinoma in situ.
- You cannot have serious heart, lung, or other medical conditions that would make the study unsafe.
- You must not be pregnant or breastfeeding, and must use effective contraception during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (cetuximab, tislelizumab, and chemotherapy) in people with advanced head and neck cancer that hasn't been treated before. The goal is to see if this mix can shrink tumors and improve outcomes.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
This trial tests two different drug combos—one using an EGFR-targeted therapy alone, the other adding an immunotherapy—before standard chemoradiation for locally advanced head and neck cancer. The goal is to see which approach works better without prior treatment.
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
This trial is for people with advanced head and neck cancer that has not been treated yet. It tests a combination of an immunotherapy drug (Pucotenlimab) and chemotherapy given before surgery to see if it can shrink tumors and improve outcomes.
This trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to treat head and neck cancer that has come back in the same area. The goal is to shrink the tumor and help your body's immune system fight the cancer.
Hear when a new LA HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.